Dosing & Uses
Graft vs Host Disease
Pending FDA approval for steroid-refractory acute graft-versus-host disease (aGvHD) grade II-IV
Next:
Pharmacology
Mechanism of Action
Monoclonal antibody that targets interleukin-2 receptor (IL-2), a cytokine that contributes to the development and proliferation of some WBCs including T-cells responsible for aGvHD
By linking specifically to the alpha-chain of the CD25 receptor, inolimomab prevents IL-2 from binding on the surface of the donor’s over-active T-cells which blocks their multiplication
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
